Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

New Adjuvant Therapy Era Builds in Melanoma

Jason Harris
Published: Monday, Nov 06, 2017
Jeffrey Weber, MD, PhD

Jeffrey Weber, MD, PhD
For decades, physicians treating patients with melanoma had 1 option with demonstrated efficacy in the adjuvant setting: interferon alfa-2B.

“There will be patients who are not good candidates for targeted therapy,” said Hauschild, who is a professor of dermatology at the University of Kiel in Germany. “There will be patients who are not good candidates for immunotherapy. That is just a practical consideration.”

Nivolumab Findings

The phase III CheckMate 238 trial included 906 patients with stages IIIB, IIIC, and IV completely resected melanoma who had ≥50% risk of relapse over 5 years. Patients were randomly assigned 1:1 to 3 mg/kg intravenous (IV) nivolumab given every 2 weeks or 10 mg/kg IV ipilimumab every 3 weeks for 4 doses, followed by 10 mg/kg every 12 weeks. The primary endpoint was RFS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication